[Skip to Navigation]
March 1962

Studies with Live Attenuated Measles-Virus Vaccine: Comparative Clinical, Antigenic, and Prophylactic Effects After Inoculation With and Without γ-Globulin

Author Affiliations

Saul Krugman, M.D., Department of Pediatrics, New York University School of Medicine, New York.; From the Department of Pediatrics, New York University School of Medicine, New York, and the Willowbrook State School, Staten Island, N.Y.; Professor and Chairman, Department of Pediatrics, New York University School of Medicine (Dr. Krugman); Assistant Professor of Pediatrics (Dr. Giles); Associate Clinical Professor of Pediatrics (Dr. Jacobs); Research Assistant (H. Friedman).

Am J Dis Child. 1962;103(3):353-363. doi:10.1001/archpedi.1962.02080020365035

The significant antigenic and protective effects of live attenuated measles-virus vaccine have been well documented.1-16 The immunologic response in children without initial measles antibodies has exceeded 95%.9 The prophylactic effect has been observed in institutional epidemics6,13 2, 10, and 15 months after immunization. All vaccinees were solidly protected under conditions which induced a 58% to 90% attack rate of measles in unvaccinated controls. In addition, intimately exposed household contacts have resisted infection after successful vaccination with live attenuated measles vaccine.

Clinical reactions to the vaccine have been limited chiefly to fever and rash. Respiratory symptoms have been minimal or absent. Among 171 susceptible children, a detectable febrile response has been reported in approximately 83% and an exanthem in 48%.9 At least 30% of susceptible vaccinees have exhibited temperature elevations exceeding 103 F. These significant febrile reactions, unless modified, would obviously limit the usefulness of this highly effective

Add or change institution